Clinical trial
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian…
NCT00061308 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00061308 |
|---|---|
| Title | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer |
| Official title | An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer |
| Intervention type | Drug |
| Interventions | Topotecan, Gemcitabine |
| Enrollment | 75 |
| Start date | Dec 1, 2002 |
| Primary completion | Sep 1, 2004 |
| First posted | May 28, 2003 |
| Last update posted | Jun 9, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: